Physicians' views on pharmacists' involvement in hospital deprescribing: A qualitative study on proton pump inhibitors.


Journal

Basic & clinical pharmacology & toxicology
ISSN: 1742-7843
Titre abrégé: Basic Clin Pharmacol Toxicol
Pays: England
ID NLM: 101208422

Informations de publication

Date de publication:
Dec 2023
Historique:
revised: 17 04 2023
received: 25 01 2023
accepted: 18 04 2023
medline: 27 11 2023
pubmed: 21 4 2023
entrez: 21 04 2023
Statut: ppublish

Résumé

Clinical pharmacists have a pivotal role in the management of the patient's medication. However, it is necessary to know how pharmacist-mediated deprescribing could be implemented in a hospital setting according to hospital physicians. To explore physicians' views on the involvement of hospital pharmacists in the deprescribing process using the example of PPIs. A qualitative study using two focus groups with hospital physicians was conducted to determine their attitudes regarding deprescribing initiated by the hospital pharmacist. The interviews were recorded and transcribed using the NVivo analysis software. A thematic analysis led to a categorization of all the verbatims. Hospital doctors are reluctant to deprescribe drugs initiated by a colleague and feel that it is the responsibility of the general practitioner (GP), who fails to do so due to lack of time. In this situation, the hospital pharmacist is in the best position to deprescribe because of his/her expertise in drug therapy. This should be a discussion between the hospital pharmacist, the hospital doctor, the GP and the patient. Deprescribing should always be adapted to the patient's context. Hospital physicians are open to a pharmacist-mediated, patient-centred approach to deprescribing as long as the GP is involved.

Sections du résumé

BACKGROUND BACKGROUND
Clinical pharmacists have a pivotal role in the management of the patient's medication. However, it is necessary to know how pharmacist-mediated deprescribing could be implemented in a hospital setting according to hospital physicians.
OBJECTIVE OBJECTIVE
To explore physicians' views on the involvement of hospital pharmacists in the deprescribing process using the example of PPIs.
METHODS METHODS
A qualitative study using two focus groups with hospital physicians was conducted to determine their attitudes regarding deprescribing initiated by the hospital pharmacist. The interviews were recorded and transcribed using the NVivo analysis software. A thematic analysis led to a categorization of all the verbatims.
RESULTS RESULTS
Hospital doctors are reluctant to deprescribe drugs initiated by a colleague and feel that it is the responsibility of the general practitioner (GP), who fails to do so due to lack of time. In this situation, the hospital pharmacist is in the best position to deprescribe because of his/her expertise in drug therapy. This should be a discussion between the hospital pharmacist, the hospital doctor, the GP and the patient. Deprescribing should always be adapted to the patient's context.
CONCLUSION CONCLUSIONS
Hospital physicians are open to a pharmacist-mediated, patient-centred approach to deprescribing as long as the GP is involved.

Identifiants

pubmed: 37081726
doi: 10.1111/bcpt.13878
doi:

Substances chimiques

Proton Pump Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

718-728

Informations de copyright

© 2023 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Références

Hilmer SN, Gnjidic D. Deprescribing: the emerging evidence for and the practice of the “geriatrician's salute”. Age Ageing. 2018;47(5):638-640. doi:10.1093/ageing/afy014
McBane SE, Dopp AL, Abe A, et al. Collaborative drug therapy management and comprehensive medication management―2015. Pharmacother J Hum Pharmacol Drug Ther. 2015;35(4):e39-e50. doi:10.1002/phar.1563
Pottegård A, Broe A, Hallas J, de Muckadell OBS, Lassen AT, Lødrup AB. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Therap Adv Gastroenterol. 2016;9(5):671-678. doi:10.1177/1756283X16650156
Othman F, Card TR, Crooks CJ. Proton pump inhibitor prescribing patterns in the UK: a primary care database study. Pharmacoepidemiol Drug Saf. 2016;25(9):1079-1087. doi:10.1002/pds.4043
Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf. 2010;19(10):1019-1024. doi:10.1002/pds.1969
Lassalle M, Le Tri T, Bardou M, et al. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol. 2020;76(3):449-457. doi:10.1007/s00228-019-02810-1
Strampelli A, Cerreta F, Vučić K. Medication use among older people in Europe: implications for regulatory assessment and co-prescription of new medicines. Br J Clin Pharmacol. 2020;86(10):1912-1920. doi:10.1111/bcp.14462
Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35-48. doi:10.1053/j.gastro.2017.04.047
Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018;11(11):1123-1134. doi:10.1080/17512433.2018.1531703
Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;37:19-24. doi:10.1016/j.ejim.2016.10.007
Voukelatou P, Vrettos I, Emmanouilidou G, et al. Predictors of inappropriate proton pump inhibitors use in elderly patients. Curr Gerontol Geriatr Res. 2019;2019:1, 7591045-5. doi:10.1155/2019/7591045
Boghossian TA, Rashid FJ, Thompson W, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;3:CD011969. doi:10.1002/14651858.CD011969.pub2
Raghunath AS, Hungin APS, Cornford CS, Featherstone V. Use of proton pump inhibitors: an exploration of the attitudes, knowledge and perceptions of general practitioners. Digestion. 2005;72(4):212-218. doi:10.1159/000089727
Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: evidence-based clinical practice guideline. Can Fam Physician Med Fam Can. 2017;63(5):354-364.
Martin P, Tamblyn R, Ahmed S, Benedetti A, Tannenbaum C. A consumer-targeted, pharmacist-led, educational intervention to reduce inappropriate medication use in community older adults (D-PRESCRIBE trial): study protocol for a cluster randomized controlled trial. Trials. 2015;16(1):266. doi:10.1186/s13063-015-0791-1
World Health Organization. Framework for Action on Interprofessional Education & Collaborative [Internet]. 2010. Accessed July 14, 2021. http://www.who.int/hrh/nursing_midwifery/en/
Santschi V, Rodondi N, Bugnon O, Burnier M. Impact of electronic monitoring of drug adherence on blood pressure control in primary care: a cluster 12-month randomised controlled study. Eur J Intern Med. 2008;19(6):427-434. doi:10.1016/j.ejim.2007.12.007
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care J Int Soc Qual Health Care. 2007;19(6):349-357. doi:10.1093/intqhc/mzm042
Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2021;128(1):4-8. doi:10.1111/bcpt.13492
Guest G, Namey E, McKenna K. How many focus groups are enough? Building an evidence base for nonprobability sample sizes. Field Methods. 2017;29(1):3-22. doi:10.1177/1525822X16639015
Hennink MM, Kaiser BN, Weber MB. What influences saturation? Estimating sample sizes in focus group research. Qual Health Res. 2019;29(10):1483-1496. doi:10.1177/1049732318821692
Rabiee F. Focus-group interview and data analysis. Proc Nutr Soc. 2004;63(4):655-660. doi:10.1079/PNS2004399
Traynor M. Focus group research. Nurs Stand (1984). 2015;29(37):44-48. doi:10.7748/ns.29.37.44.e8822
Gundumogula M. Importance of focus groups in qualitative research. Int J Humanit Soc Stud. 2020;8(11). doi:10.24940/theijhss/2020/v8/i11/HS2011-082
Gould D. Using vignettes to collect data for nursing research studies: how valid are the findings? J Clin Nurs. 1996;5(4):207-212. doi:10.1111/j.1365-2702.1996.tb00253.x
Norwich B. The role of vignettes in the research of emotional and behaviour difficulties. Emot Behav Diffic. 2001;6(1):50-62. doi:10.1080/13632750100507655
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77-101. doi:10.1191/1478088706qp063oa
Corden A, Sainsbury R. Exploring ‘quality’: research Participants' perspectives on verbatim quotations. Int J Soc Res Methodol. 2006;9(2):97-110. doi:10.1080/13645570600595264
Sawan M, Reeve E, Turner J, et al. A systems approach to identifying the challenges of implementing deprescribing in older adults across different health-care settings and countries: a narrative review. Expert Rev Clin Pharmacol. 2020;13(3):233-245. doi:10.1080/17512433.2020.1730812
Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544. doi:10.1136/bmjopen-2014-006544
Palagyi A, Keay L, Harper J, Potter J, Lindley RI. Barricades and brickwalls - a qualitative study exploring perceptions of medication use and deprescribing in long-term care. BMC Geriatr. 2016;16(1):15. doi:10.1186/s12877-016-0181-x
Spinewine A, Swine C, Dhillon S, et al. Appropriateness of use of medicines in elderly inpatients: qualitative study. BMJ. 2005;331(7522):935. doi:10.1136/bmj.38551.410012.06
Nixon MS, Vendelø MT. General practitioners' decisions about discontinuation of medication: an explorative study. J Health Organ Manag. 2016;30(4):565-580. doi:10.1108/JHOM-01-2015-0011
Whitman A, DeGregory K, Morris A, Mohile S, Ramsdale E. Pharmacist-led medication assessment and deprescribing intervention for older adults with cancer and polypharmacy: a pilot study. Support Care Cancer. 2018;26(12):4105-4113. doi:10.1007/s00520-018-4281-3
Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults. Jama. 2018;320(18):1889-1898. doi:10.1001/jama.2018.16131
SaferMedsNL. Promoting safe and effective medication use for people living in Newfoundland and Labrador. 2018. Accessed March 8, 2023. https://safermedsnl.ca/
Bundeff AW, Zaiken K. Impact of clinical pharmacists' recommendations on a proton pump inhibitor taper protocol in an ambulatory care practice. J Manag Care Pharm. 2013;19(4):325-333. doi:10.18553/jmcp.2013.19.4.325
Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30(10):793-807. doi:10.1007/s40266-013-0106-8
Litosseliti L. Using Focus Groups in Research. A&C Black; 2003.

Auteurs

Pauline Gendre (P)

CHU Nantes, Pharmacy Department, Nantes University, Nantes, France.

Severine Mayol (S)

Faculty of Sociology, Nantes University, Nantes, France.

Julie Mocquard (J)

CHU Nantes, Pharmacy Department, Nantes University, Nantes, France.

Jean-François Huon (JF)

CHU Nantes, Pharmacy Department, Nantes University, Nantes, France.
INSERM, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH